Photo by nci from unsplash
More potent anti-thrombotic strategies have been shown to reduce major adverse limb events (MALE) in patients with atherosclerosis. Ticagrelor is a potent P2Y12 inhibitor that reduces major adverse cardiovascular events… Click to show full abstract
More potent anti-thrombotic strategies have been shown to reduce major adverse limb events (MALE) in patients with atherosclerosis. Ticagrelor is a potent P2Y12 inhibitor that reduces major adverse cardiovascular events (MACE) in stable patients with prior myocardial infarction and in those with
Keywords:
events systematic;
adverse limb;
ticagrelor major;
limb events;
major adverse
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!